{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"63.5","upperLimit":"84.9","value":"75.4"},{"groupId":"OG001","lowerLimit":"43.3","upperLimit":"55.0","value":"49.2"}]}],"title":"Patient-level CDR - Central Reader 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"65.1","upperLimit":"86.1","value":"76.8"},{"groupId":"OG001","lowerLimit":"39.7","upperLimit":"51.3","value":"45.5"}]}],"title":"Patient-level CDR - Central Reader 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"61.9","upperLimit":"89.7","value":"73.9"},{"groupId":"OG001","lowerLimit":"40.7","upperLimit":"52.3","value":"46.5"}]}],"title":"Patient-level CDR - Central Reader 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"52.0","upperLimit":"69.8","value":"60.9"},{"groupId":"OG001","lowerLimit":"37.7","upperLimit":"47.0","value":"42.4"}]}],"title":"Region-level PPV - Central Reader 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"57.6","upperLimit":"76.4","value":"67.0"},{"groupId":"OG001","lowerLimit":"51.7","upperLimit":"64.0","value":"57.9"}]}],"title":"Region-level PPV - Central Reader 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"53.5","upperLimit":"71.8","value":"62.6"},{"groupId":"OG001","lowerLimit":"43.8","upperLimit":"55.3","value":"49.5"}]}],"title":"Region-level PPV - Central Reader 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"297"}],"units":"Participants"}],"description":"Patient-level CDR was defined as the percentage of all patients scanned who had at least one TP lesion (localized correspondence between rhPSMA-7.3 (18F) PET imaging and the reference standard) regardless of any co-existing FP findings.\n\nRegion-Level PPV is defined as the regions which are true positive out of all regions with positive lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with Histopathology available as SoT","id":"OG000","title":"Histopathology Available as SoT"},{"description":"Patients without histopathology available as SoT","id":"OG001","title":"Histopathology Not Available as SoT"}],"paramType":"NUMBER","populationDescription":"Efficacy Analysis Population (EAP): all patients who received rhPSMA-7.3 (18F) injection followed by a PET/CT scan and for whom sufficient data are available to permit a clear classification following the SoT algorithm.","reportingStatus":"POSTED","timeFrame":"Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan","title":"Patient-level CDR and Region-level PPV of rhPSMA-7.3 (18F) PET for Recurrence in Those Patients With and Without Reference Standard Histopathology Available","type":"SECONDARY","unitOfMeasure":"percentage"}